In 2018, the German Federal Institute for Risk Assessment (BfR) informed the European Commission (EC) that they were concerned that the use of prostaglandins and their analogues in cosmetic products might pose risks for consumers (BfR, 2018; SCCS, 2022).
Following a call for data in 2020, the EC requested the Scientific Committee on Consumer Safety (SCCS) to carry out a safety assessment of the uses of prostaglandins and their analogues in cosmetic products. In February 2022, SCCS concluded that the safe use concentrations for prostaglandinanalogues (‘PGAs’) in cosmetic products could not be determined due to the scarcity of toxicological data on the ingredients. However, SCCS said that it would be ready to assess any new ingredient-based evidence provided to support safe use (SCCS, 2022).